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Evaluation of Test Characteristics for Outcome
Measures Used in Raynaud’s Phenomenon
Clinical Trials
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Objective. Randomized controlled trials (RCTs) in Raynaud’s phenomenon (RP) have shown conflicting efficacy data.
Also, there is no consensus on the outcome measures that should be used. Our objectives were to assess the reliability of
individual core set measures used in 3 RCTs, evaluate the placebo response for individual core set measures, and
determine if a composite of individual core set measures will decrease the placebo response, which may improve our
ability to see treatment effects in future trials.
Methods. We analyzed core set measures from 249 patients in the placebo-treated groups from 3 RCTs. Core set measures
analyzed included the Raynaud’s Condition Score (RCS); patient and physician assessment of RP; pain, numbness, and
tingling during an RP attack; average number of attacks/day; and duration of attacks. Intraclass correlation coefficients
(ICCs) were calculated during the run-in period to the RCTs.
Results. ICCs of >0.70 were observed for the RCS, attack symptoms, and average attacks/day. A high placebo response
rate was observed for all individual core measures except the duration of attacks. For the RCS, the placebo response
ranged from 56% with >10% improvement to 19.5% with >60% improvement. In contrast, placebo response rates of
10–20% were observed when several core set measures were combined to develop a composite score.
Conclusion. Outcome measures used in RCTs of RP are associated with marked variability. A combination of outcome
measures is associated with low placebo responses. Future studies are needed to assess if a composite score will be able
to differentiate placebo from an effective agent.
INTRODUCTION
Raynaud’s phenomenon (RP) is a condition where there is
vasospasm of blood vessels, caused by an imbalance of
vasoconstricting and vasodilating factors, resulting in de-
creased blood flow in the extremities, causing anoxia, par-
oxysmal pallor, and/or cyanosis. This recurrent ischemia
can eventually result in loss of function of the fingers or
toes and in extreme cases, gangrene or even amputation
(1). Primary RP is generally thought to be induced (e.g.,
cold, emotions), whereas secondary RP tends to be associ-
ated with other diseases that have endothelial abnormali-
ties (e.g., systemic sclerosis [SSc]), but can be exacerbated
by factors known to precipitate primary RP. Although the
prevalence of secondary RP is difficult to characterize,
since it depends on the underlying disorder, prevalence
rates of primary RP have been reported to be 11% in
women and 8% in men in the US, with yearly incidence
rates of 2.2% and 1.5%, respectively (2). RP is usually
associated with a detrimental effect on day-to-day activi-
ties, and secondary RP is an important contributing factor
for developing digital ulcers and ischemia (2).
Previous clinical trials have used different core set mea-
sures to assess efficacy and have included patient-reported
frequency and duration of RP attacks, RP attack symptoms
(such as pain, numbness, and tingling), the Raynaud’s
Condition Score (RCS), and patient and physician global
assessments of RP. These studies have differed in the
outcome measures used and the primary outcome measure
specified. This is reminiscent of the 1980s, when rheuma-
toid arthritis (RA) trials were being conducted with a lack
of consensus on a group of core set outcome measures to
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assess efficacy. The lack of uniform outcome measures
impedes drug development and hampers the meta-
analysis to assess efficacy.
In this study, our objectives were to 1) assess the reli-
ability of individual core set measures used in randomized
controlled trials (RCTs) of RP, 2) evaluate the placebo
response for individual core set measures in RCTs, and
3) determine if a composite of individual core set measures
will decrease the placebo response. We used the placebo
data from 3 large RCTs that assessed efficacy using a novel
preparation of nitroglycerin in patients with primary and
secondary RP.
PATIENTS AND METHODS
Patients. We analyzed the placebo-treated groups from
3 RCTs (MediQuest Therapeutics). No patient participated
in more than 1 trial. Data were collected from a total of 249
placebo-treated patients with primary or secondary RP
conducted in the US during the period 2006–2008. All
types of secondary RP patients were included in the 3
studies. Each patient with secondary RP was then identi-
fied by the type of primary disease; the majority of the
patients had SSc.
Clinical trial descriptions. Study 05-002 (ClinicalTrials.
gov identifier: NCT00266669) was a multicenter, placebo-
controlled RCT enrolling 219 subjects with a clinical di-
agnosis of primary RP or secondary RP due to a connective
tissue disease, with 108 assigned to the placebo group (3).
The subjects discontinued vasodilator therapies for 2
weeks, followed by a 2-week single-blind placebo run-in
phase to assess disease severity. Those with at least 5 RP
attacks during a 7-day period entered the 4-week double-
blinded portion of the study. The subjects were randomly
assigned to receive placebo or 0.9% MQX-503, a micro-
emulsion formulation of topical nitroglycerin for rapid
local delivery with less systemic side effects, and were
instructed to apply the gel immediately before or within 5
minutes of an RP event (maximum of 4 applications daily).
The subjects used an electronic diary to record each gel
application and/or RP event. Each day, the subjects re-
corded an RCS using a visual analog scale (VAS) from
0–10, where 0  no difficulty with RP and 10  extreme
difficulty with RP, and a composite self-assessment of the
severity of RP rated on a VAS from 0–10, where 0  no
attacks and 10  severe attacks. The primary outcome was
the change in the mean RCS at the target week (the treat-
ment week that matched the run-in period in terms of
ambient temperature) compared to baseline (run-in pe-
riod).
Study 06-004/5 (ClinicalTrials.gov identifier: NCT004-
19419) was a randomized double-blind crossover study in
patients with moderate to severe primary RP or secondary
RP due to a connective tissue disease that enrolled 110
patients (57 randomized to the placebo group and 53 ran-
domized to the MQX-503 group). The subjects discontin-
ued vasodilator therapy for 2 weeks, followed by a 2-week
placebo run-in period to assess disease activity. This was
followed by 6 weeks of treatment in a crossover design: 3
weeks of receiving an active drug followed by 3 weeks of
receiving placebo versus 3 weeks of receiving placebo
followed by 3 weeks of receiving an active drug. The
subjects were then followed for 1 week after the last treat-
ment visit. The primary outcome was to assess changes in
the RCS scores. The subjects used an electronic diary to
record each treatment and/or RP event. Each day, the
subjects recorded the RCS and self-assessment of the RP
severity.
Study 07-005 (ClinicalTrials.gov identifier: NCT005-
77304) was a randomized double-blind crossover study
that recruited a total of 164 patients with moderate to
severe primary RP or secondary RP due to a connective
tissue disease, with 84 assigned to the placebo group. The
subjects were allowed to continue vasodilator therapy at a
stable dose. There was a 2-week run-in period to evaluate
baseline disease activity. Subjects were given pouch ap-
plicators of either the nitroglycerin preparation or placebo
for use on both hands up to 5 minutes prior to an antici-
pated RP attack or up to 5 minutes after the beginning of an
actual attack. The patients were limited to 4 applications
daily, with at least 2 hours between applications. The
primary outcome was the change in the RCS scores. The
subjects used an electronic diary to record each gel appli-
cation and/or RP event. Each day, the subjects recorded
the RCS and self-assessment of the severity of RP.
Core set measures analyzed in 3 RCTs. Eight core set
measures were assessed from the patients in these 3 stud-
ies, including physician assessment of RP (0–100 VAS)
and the following patient-reported outcome measures: the
RCS (0–10 VAS); patient assessment of RP (0–100 VAS);
pain, numbness, and tingling with each attack (0–100
VAS); average number of attacks per day; and duration of
attacks. Daily patient logs of RP attacks were used to com-
pute the average number of attacks per day; the average
duration of attacks; the daily averages of patient-reported
pain, numbness, and tingling associated with each re-
ported attack; and a daily RCS. Patient and physician
assessments of RP were recorded weekly. Daily averages
were used to compute weekly averages for the period
between physician visits, and the weekly averages were
averaged for the run-in period and for the treatment pe-
riod. The percent improvement between the run-in and
treatment periods was calculated for 8 core set measures.
Statistical analysis. The reliability of the outcome mea-
sures between the run-in period and treatment periods was
Significance & Innovations
● Outcome measures currently used in Raynaud’s
phenomenon clinical trials show marked intra-
rater variability and are associated with a high
placebo response in an analysis of 3 large random-
ized controlled trials.
● A composite index of the individual outcome mea-
sures is associated with a reduction in the measure-
ment variability and a lower placebo response.
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2  the between-subject variation and 
2  the
within-subject variation. The ICC was assessed during the
run-in period before the patients were randomized to their
group. Our hypothesis was that if the outcome measures
are reliable, they should not differ appreciably between
the run-in and treatment periods, and the ICC should be
high. An ICC of 0.70 was considered satisfactory for
group comparisons (4).
Also, for the current analysis, the pain, numbness, and
tingling symptoms of RP attacks had high correlation co-
efficients (range 0.77–0.78), and were grouped together
into attack symptoms by selecting the percent improve-
ment of the outcome with the highest degree of improve-
ment. This resulted in 6 individual core set measures. We
also assessed preliminary definitions of improvement and
required X% improvement in Y of the 6 variables, where
X was set at 10%, 20%, 30%, 40%, 50%, and 60% and Y
was set as 2, 3, 4, 5, or 6 variables, similar to the analysis
performed by Paulus et al (5).
RESULTS
Patient characteristics. A total of 249 patients receiving
placebo were included in the analysis. The mean  SD age
of the subjects in the 3 RCTs was 47.5  12.4 years, 92%
were women, 80% were non-Hispanic whites, and 53%
had secondary RP (Table 1). Baseline scores for the out-
come measures are shown in Table 1. There were no base-
line differences in the demographics between primary RP
versus secondary RP groups. In comparing baseline scores







Age, mean  SD years 47.5  12.4 49.2  11.1 45.5  13.4
Female sex, no. (%) 230 (92.4) 124 (93.9) 106 (90.6)
Race, no. (%)
White 200 (80.3) 98 (74.2) 102 (87.2)
African American 20 (8.0) 15 (11.4) 5 (4.3)
Hispanic 10 (4.0) 5 (3.8) 5 (4.3)
Asian/Pacific Islander 14 (5.6) 10 (7.6) 4 (3.4)
Other 5 (2.0) 4 (3.0) 1 (0.9)
Baseline score, %
Patient assessment of RP (0–100 VAS)
N 249 132 117
Mean  SD 53.6  17.6 54.1  17.3 53  17.9
Physician assessment of RP (0–100 VAS)
N 249 132 117
Mean  SD 48.2  18.7 48.5  19.1 47.8  17.9
Attack symptoms (range 0–100)
N 215 117 98
Mean  SD 34.6  23.0 31.4  22 38.6  23.4
Pain (range 0–100)†
N 223 120 103
Mean  SD 33.1  23.3 29.4  22.7 37.3  23.4
Tingling (range 0–100)†
N 223 120 103
Mean  SD 30.9  22.8 28.3  21.3 33.9  24.2
Numbness (range 0–100)†
N 223 120 103
Mean  SD 41.7  24.8 38.3  24.9 45.8  24.1
Average attacks per day‡
N 247 132 115
Mean  SD 2.1  1.4 2.3  1.5 1.9  1.3
Duration of attacks, minutes
N 221 119 102
Mean  SD 28.4  16.0 28.1  14.1 28.8  18.0
RCS (range 0–10)‡
N 247 132 115
Mean  SD 3.6  2.0 3.5  2.1 3.6  1.9
* P  0.05 for attack symptoms, pain, tingling, and the Raynaud’s Condition Score (RCS) between primary versus secondary
Raynaud’s phenomenon (RP). All other comparisons are not significant at P  0.05. VAS  visual analog scale.
† Data not available for 26 patients.
‡ Data not available for 2 patients.
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between primary RP versus secondary RP groups, patients
with primary RP had fewer RP attacks (P  0.05). In
contrast, pain and numbness were significantly greater in
patients with primary RP (Table 1).
ICCs. The patients had a high degree of variability in
their core set measures. The ICC was acceptable for the
RCS, attack symptoms, and average attacks/day (ICCs
0.70). Patient and physician global assessments and the
duration of attacks had ICCs 0.70 (Table 2). The ICCs for
the individual studies are shown in Supplementary Ap-
pendix A (available in the online version of this article
at http://onlinelibrary.wiley.com/doi/10.1002/acr.21858/
abstract) and show variability within the 3 RCTs. For ex-
ample, the ICCs ranged from 0.47–0.71 for the RCS in the
3 trials. The ICCs were similar between patients with pri-
mary and secondary RP (Table 2).
Change in individual outcome measures for a given
level of improvement. We also assessed the variability in
different core set measures by calculating the change in
each core set measure for a given level of improvement
(range from 10 to 60% improvement) (Table 3). There
was generally a high placebo response for all individual
core set measures (except duration of attacks, which
ranged from 1.4–36.3%). As an example, for the RCS, the
placebo response ranged from 56% with 10% improve-
ment to 19.5% with 60% improvement. The mean pla-
cebo response for all 3 trials is shown in Figure 1 and the
range of the 3 trials is shown in Supplementary Appendix
B (available in the online version of this article at http://
onlinelibrary.wiley.com/doi/10.1002/acr.21858/abstract).
Change in percent improvement in core set measures in
relation to the number of outcome measures examined.
Similar to the development of the criteria by Paulus et al
(5), we explored if the simple arithmetic combination of
percent improvement using 6 core set measures would
result in a decreased placebo response. Therefore, we as-
sessed the percent improvement relative to the number of
core set measures included in the analysis (Figures 1 and
2). Of the placebo-treated patients, 92.8% showed 10%
improvement in at least 1 core set measure (Figure 2D),
with 38.5% showing 60% improvement in at least 1 core
set measure. An increased percent improvement along
with combining core set measures decreased the placebo
response rate. For example, 78% of patients had an im-
provement in the individual core set measures by 30%
for 1 of 6 core set measures, 53% for 2 of 6 measures, 39%
for 3 of 6 measures, 26% for 4 of 6 measures, 13% for 5 of
6 measures, and 2% for 6 of 6 measures (Figure 2B). There
were no significant differences between primary and sec-
ondary RP (see Supplementary Appendices C and D, avail-
able in the online version of this article at http://online
Table 2. Intraclass correlation coefficient analysis among the different core set measures








Patient assessment of RP (VAS) 0.47 0.49 0.46
Physician assessment of RP (VAS) 0.54 0.52 0.57
Attack symptoms 0.76 0.78 0.72
Pain during RP attack (VAS) 0.78 0.79 0.76
Numbness during RP attack (VAS) 0.77 0.81 0.70
Tingling during RP attack (VAS) 0.77 0.76 0.79
Average attacks/day 0.79 0.75 0.86
Duration of the attacks, minutes 0.61 0.63 0.61
Raynaud’s Condition Score 0.70 0.74 0.65
* RP  Raynaud’s phenomenon; VAS  visual analog scale.
† Units for each core set measure are provided in Table 1.
Table 3. Proportion of patients who achieved a predefined percentage of improvement for each












60% 13.9 14.7 1.4 10.3 19.5 22.3
50% 21.2 20.8 1.9 21.4 22.4 32.1
40% 29.4 31.0 4.7 31.3 29.0 41.4
30% 45.3 39.6 6.5 43.6 35.3 50.7
20% 55.5 53.5 14.4 51.4 45.6 62.3
10% 66.1 64.1 26.0 63.4 56.0 71.2
10% 74.7 75.1 36.3 72.8 65.1 77.2
* Values are the percentage of patients showing the specified level of improvement for each core set measure.
RCS  Raynaud’s Condition Score.




Current pharmacologic therapies used to treat RP have
modest efficacy and include agents such as calcium-
channel blockers, angiotensin II antagonists, 1-adrenergic
blockers, and selective serotonin reuptake inhibitors (6).
Apart from calcium-channel blockers, which are consid-
ered the first-line therapy, and prostacyclins for severe
cases in patients with secondary RP, evidence for the
effects of other agents is limited and side effects are com-
mon (6–8). RCTs of RP have used different outcome mea-
sures, and the results have been conflicting. This is likely
due to the episodic nature of RP and lack of standardiza-
tion of outcome measures. Using placebo data from 3 large
RCTs, we show that outcome measures in RP have marked
intrarater variability and are associated with a high pla-
cebo response. In addition, the composite index of the
individual outcome measures reduces the measurement
variability and placebo response.
Meta-analyses of RP trials have shown modest efficacy
of current pharmacologic agents (9,10). In addition, trials
have provided conflicting results. For example, in an RCT
of oral iloprost in 103 patients with RP secondary to SSc
(11) that evaluated the frequency of RP, daily duration of
RP, severity of RP, and physician global assessment of RP
as outcome measures, the duration and severity of RP
showed a statistical improvement after 6 weeks of active
treatment versus the placebo group. However, in another
trial of 308 patients with RP secondary to SSc (12) that
evaluated the average duration of RP attacks, average
number of RP attacks, and RCS, there was no statistical
improvement in the iloprost group versus the placebo
group. More recently, tadalafil was assessed in RP in
double-blind, placebo-controlled RCTs. One RCT showed
improvement in the RCS and duration and frequency of
attacks compared to the placebo group (13), whereas the
other RCT that evaluated the RCS and frequency and du-
ration of RP attacks failed to show a statistically significant
difference compared to the placebo group in any outcome
measure (14). The above data highlight the difficulty in
determining whether pharmacologic interventions are ef-
ficacious, since there is no standardization of outcome
measures in RCTs of RP (13,15).
The lack of reliable biomarkers or surrogate end points
in RP that reliably predict efficacy has required that inves-
tigators utilize end points that can result in high placebo
response rates due to the variability in these core set mea-
Figure 1. Percentage of patients showing improvement in the 6
core set measures. The data show the mean improvement for all 3
clinical trials. RCS  Raynaud’s Condition Score.
Figure 2. Percentage of patients showing improvement when assessing 1–6 core set measures.
Plots show improvement over the range of 10% improvement to 40% improvement (A–D), as
assessed against the number of core set measures included in the analyses.
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sures between patients. Using varied core set measures
between trials, however, makes it impossible to compare
trial results, and in some cases the absence of core set
measures may make investigators decide which outcome
measures to report and may only report those that show
significance. In addition, using a parameter insensitive to
change will result in a therapy that may have otherwise
showed activity being scored as ineffective. This has ham-
pered the approval of new drugs for RP and left physicians
with minimal options for treatment.
In the 1980s, patients with RA also showed similar
variability in individual core set measures when attempt-
ing to measure drug efficacy (16). Approximately 10 dif-
ferent individual core set measures had been used in an
attempt to gauge the efficacy of new agents in RA. How-
ever, due to statistical chance, the possibility that any one
parameter will change in response to therapy made RCTs
difficult to interpret. This was first addressed by Paulus
et al, who proposed a composite score based on statis-
tical analysis to gauge the activity of disease-modifying
antirheumatic drugs (DMARDs) (5). These criteria, known
as the Paulus criteria, required the improvement of 20%
in each of 4 of the following 6 core set measures: morn-
ing stiffness, erythrocyte sedimentation rate, joint pain/
tenderness index, joint swelling score, patient overall as-
sessment of current disease severity, and physician overall
assessment of current disease severity. In the initial ana-
lysis, very few placebo-treated patents qualified for im-
provement, whereas significantly more patients treated
with DMARDs improved. A consistently low placebo re-
sponse is essential for any composite score to ensure that
responses observed with an agent represent real improve-
ments. The Paulus criteria were later modified to develop
the American College of Rheumatology 20% improvement
criteria (ACR20) (17), the gold standard for approval of
drugs by regulatory agencies for RA.
Using methodology similar to the Paulus criteria, our
analysis suggests a composite index for RP that can de-
crease the placebo response rate to an acceptable level,
allowing for a better evaluation of a therapeutic efficacy
with new treatments. The choice of how many core set
measures should be combined and whether a certain per-
cent improvement in the RCS and patient global assess-
ment is required (similar to the ACR20, where 20% im-
provement in the swollen joint count and tender joint
count is required) need to be determined in future studies.
Further, some of these individual measures, although
widely used, are subjective, and it is debatable whether
they should be included. It also needs to be determined if
a combination of individual core set variables will lead to
higher discrimination between an effective drug versus
placebo in RP. If predictive of efficacy, this composite
index will enhance our ability to evaluate new therapies
for patients with RP and should expedite approvals in this
area of high medical need.
Other studies have evaluated core set measures and
response measures in RP. Using data from a large RCT of
oral iloprost in SSc and RP, Merkel and colleagues con-
ducted a factor analysis and found 4 factors; of these, 2
factors assessed RP-associated disease activity and sever-
ity measures and the other 2 captured digital ulcers and
mood/tension measures (18). All RP measures are in-
cluded in the current study and formed the basis of this
core set. In addition, we captured tingling and numbness
during an acute attack of RP, since these are common
symptoms in patients with RP (18). In another study,
Khanna et al estimated the minimum clinically important
improvement from one of the trials (19), and found that an
improvement of 1.4–1.5 points in the RCS (0–10 scale)
met the minimum clinically important difference crite-
rion. However, this analysis did not address the variability
of the RCS and the placebo response.
Our study has many strengths. First, we included pa-
tients from 3 large RCTs of RP where individual patient
data were available. Second, uniform core set measures
were incorporated in these studies, providing strength to
our analysis. We have carefully evaluated the psycho-
metric characteristics of the core set measures.
Our study is not without limitations. Lack of an effective
therapeutic agent makes it difficult to assess if a composite
index would be successful in discriminating an effective
drug versus placebo. However, this study did not assess
this, since 2 of 3 primary trials have not yet been published
and the data were not available to evaluate. Future studies
will evaluate this deficiency in the context of this and
other trials.
In conclusion, analysis of placebo groups from 3 large
RCTs shows that there is marked variability in the indi-
vidual core set measures used in RP clinical trials, and that
a combination of these variables reduces variability.
Figure 3. Percentage of patients with a given improvement in
core set measures. The data show the percentage of patients with
a given level of improvement for all 6 core set measures for A,
secondary Raynaud’s phenomenon (RP) patients, and B, primary
RP patients. RCS  Raynaud’s Condition Score.
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